Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone.

Archives of pharmacal research - 1 Aug 2023

Byeon Ji-Young, Cho Chang-Keun, Kang Pureum, Kim Se-Hyung, Jang Choon-Gon, Lee Seok-Yong, Lee Yun Jeong

Abstract excerpt

Tolperisone, a muscle relaxant used for post-stroke spasticity, is metabolized to its main metabolite by CYP2D6 and to a lesser extent by CYP2C19 and CYP1A2. We investigated the effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on tolperisone pharmacokinetics. A 150 mg oral dose of tolperisone was given to 184 healthy Korean subjects and plasma concentrations of tolperisone were measured...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cigarette Smoking

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Polymorphism, Genetic

Share to Tandem Mass Spectrometry

Source

Identifiers

PMID: 37728834
DOI: 10.1007/s12272-023-01462-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone.PMID 37728834Read ↗

Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects.Semantic proximity Read ↗

Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.Semantic proximity Read ↗

Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.Semantic proximity Read ↗

Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.Semantic proximity Read ↗

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.Semantic proximity Read ↗

Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes.Semantic proximity Read ↗

In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.Semantic proximity Read ↗

Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.Semantic proximity Read ↗

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.Semantic proximity Read ↗

Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.